MET and Miyoshi myopathy: A confirmation of the involvement of c-MET in disease progression was recently provided by Zhang et al.[44], through the determination of the prevalence of c-MET overexpression in a publicly available gene expression profiling database of myeloma: c-MET resulted in being significantly higher in MGUS (n = 44) vs. healthy controls (n = 22), and even significantly much higher in a large cohort of newly diagnosed MM cases (n = 599), in association with poor outcomes[44].